

Notice to 340B covered entities regarding TRUQAP® Replenishment

Two different package forms of TRUQAP® Capivasertib (Bottles and Blister pack Wallet) are currently available in the United States. The 160mg Bottle NDC will be discontinued by December 31, 2024. In light of this discontinuance, AstraZeneca is hereby providing notice that it voluntarily agrees that covered entities utilizing virtual inventory management with a 340B inventory replenishment model may count accumulations of the 160mg Blister Pack wallet NDC toward replenishment of equal quantities of the corresponding 160mg Bottle NDC.

AstraZeneca has additionally launched the same package forms for the 200mg NDCs. Although the 200mg bottle is not being discontinued, for avoidance of doubt, AstraZeneca is hereby providing notice that it agrees that covered entities utilizing virtual inventory management with a 340B inventory replenishment model may replenish the 200mg bottle NDC of TRUQAP with the 200mg Blister Pack Wallet NDC as long as appropriate amounts are replenished.

TRUQAP® (Capivasertib)	Strength	NDC	Order Quantity
Bottle	160mg	00310-9500-01	1x64ct Bottle
Blister Pack	160mg	00310-9500-02	4x16ct Blister Pack
Bottle	200mg	00310-9501-01	1x64ct Bottle
Blister Pack	200mg	00310-9501-02	4x16ct Blister Pack

Please direct questions to: azusgovernmentpricing@astrazeneca.com